World Intrahepatic Cholangiocarcinoma (ICC) Pipeline Insight Report 2019 - ResearchAndMarkets.com

The "Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines.

The assessment part of the report embraces, in depth Intrahepatic Cholangiocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intrahepatic Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Intrahepatic Cholangiocarcinoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Intrahepatic Cholangiocarcinoma targeted therapeutics development with respective active and dormant or discontinued projects.

Intrahepatic Cholangiocarcinoma pipeline report covers 17+ companies. Some of the key players include Delcath Systems (Melphalan/HDS), Sirnaomics (STP705), RedHill Biopharma (Opaganib), etc.

Scope of the report

• The Intrahepatic Cholangiocarcinoma report provides an overview of therapeutic pipeline activity for Intrahepatic Cholangiocarcinoma across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Intrahepatic Cholangiocarcinoma therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Intrahepatic Cholangiocarcinoma Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Intrahepatic Cholangiocarcinoma
  
  

Key Topics Covered:

1. Report Introduction

2. Intrahepatic Cholangiocarcinoma

2.1. Intrahepatic Cholangiocarcinoma Disease Overview

2.2. Intrahepatic Cholangiocarcinoma History

2.3. Intrahepatic Cholangiocarcinoma Symptoms

2.4. Intrahepatic Cholangiocarcinoma Causes

2.5. Intrahepatic Cholangiocarcinoma Pathophysiology

2.6. Intrahepatic Cholangiocarcinoma Diagnosis

2.6.1. Diagnostic Guidelines

3. Intrahepatic Cholangiocarcinoma Current Treatment Patterns

3.1. Treatment Guidelines

4. Intrahepatic Cholangiocarcinoma - An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Intrahepatic Cholangiocarcinoma companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Intrahepatic Cholangiocarcinoma Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Intrahepatic Cholangiocarcinoma Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. Intrahepatic Cholangiocarcinoma Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.2.1. Comparative Analysis

5.3. Early Stage Products (Phase-I)

5.3.1. Comparative Analysis

5.4. Pre-clinical and Discovery Stage Products

5.4.1. Comparative Analysis

5.5. Inactive Products

6. Intrahepatic Cholangiocarcinoma - Products Analysis

6.1. Product Profiles

6.1.1. Melphalan: Delcath Systems

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

6.1.2. STP705: Sirnaomics

6.1.3. Opaganib: RedHill Biopharma

7. Recent Technologies

8. Intrahepatic Cholangiocarcinoma Key Companies

8.1. ArQule

8.2. H3 Biomedicine

8.3. Delcath System

8.4. Sirnaomics

8.5. RedHill Biopharma

8.6. Roche

8.7. Forma Therapeutics

8.8. Jiangsu Hengrui Medicine

8.9. Biocompatibles International

8.10. LSK BioPartners

8.11. Eisai Co Ltd

8.12. Array BioPharma

8.13. Bayer Healthcare

8.14. Taiho Oncology

8.15. Sirtex Medical

8.16. MedImmune

8.17. Rafael Pharmaceuticals

9. Intrahepatic Cholangiocarcinoma Key Products

9.1. Derazantinib

9.2. H3B 6527

9.3. Melphalan (Primary)

9.4. STP 705

9.5. Opaganib

9.6. Capecitabine (Primary) ; Yttrium-90 (Primary)

9.7. FT 2102

9.8. Camrelizumab

9.9. Irinotecan-eluting beads

9.10. Rivoceranib

9.11. Lenvatinib

9.12. Varlitinib

9.13. Regorafenib

9.14. Futibatinib

9.15. Cisplatin-gemcitabine

9.16. Durvalumab

9.17. CPI 613

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Intrahepatic Cholangiocarcinoma - Unmet Needs

12. Intrahepatic Cholangiocarcinoma - Future Perspectives

13. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/g6xgyn

View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005468/en/